FDA Maps Out Potential 510(k) Reforms In Long-Awaited Report
This article was originally published in The Pink Sheet Daily
Executive Summary
At first blush, industry organizations agree changes could be viewed as positives for device makers, but the ultimate impact of the proposals will depend on how they are implemented.
You may also be interested in...
Broad 510(k) Reform Still On The Table; IOM Panel Enters Closed-Door Phase
The Institute of Medicine committee charged with recommending reforms to FDA's 510(k) clearance program will move the remainder of its efforts behind closed doors
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.